Giusti, Betti <br/><br/>
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.  [electronic resource] 

 -  Pharmacogenetics and genomics  Dec 2007 
 - 1057-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-6872 
<br/><br/><label>Standard No.: </label>10.1097/FPC.0b013e3282f1b2be  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--blood<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Aspirin--therapeutic use<br/>Clopidogrel<br/>Cytochrome P-450 CYP2C19<br/>Cytochrome P-450 CYP3A<br/>Cytochrome P-450 Enzyme System--genetics<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Mixed Function Oxygenases--genetics<br/>Pharmacogenetics<br/>Platelet Aggregation--drug effects<br/>Platelet Aggregation Inhibitors--metabolism<br/>Polymorphism, Genetic<br/>Receptors, Purinergic P2--genetics<br/>Receptors, Purinergic P2Y12<br/>Ticlopidine--analogs & derivatives